Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05710185 · ClinicalTrials.gov registry record · Phase 4
Deucravacitinib for the Treatment of Palmoplantar Pustulosis
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT05710185 is a Phase 4 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 3 participants.
The verdict
NCT05710185, a Phase 4 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.
Interventions
- DRUG Deucravacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05710185
The ClinicalTrials.gov registry entry for NCT05710185 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Deucravacitinib is the first listed.
NCT05710185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05710185 about?
NCT05710185 is a clinical study titled "Deucravacitinib for the Treatment of Palmoplantar Pustulosis". A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.
What is the current status of trial NCT05710185?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2023-07-01. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT05710185?
The interventions under investigation include: Deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT05710185?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.